Literature DB >> 22236009

Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection.

J Cowan1, S Pandey, L G Filion, J B Angel, A Kumar, D W Cameron.   

Abstract

In this study, we investigated the role and expression of T helper type 17 (Th17) cells and Th17 cytokines in human tuberculosis. We show that the basal proportion of interferon (IFN)-γ-, interleukin (IL)-17- and IL-22-expressing CD4(+) T cells and IL-22-expressing granulocytes in peripheral blood were significantly lower in latently infected healthy individuals and active tuberculosis patients compared to healthy controls. In contrast, CD4(+) T cells expressing IL-17, IL-22 and IFN-γ were increased significantly following mycobacterial antigens stimulation in both latent and actively infected patients. Interestingly, proinflammatory IFN-γ and tumour necrosis factor (TNF)-α were increased following antigen stimulation in latent infection. Similarly, IL-1β, IL-4, IL-8, IL-22 and TNF-α were increased in the serum of latently infected individuals, whereas IL-6 and TNF-α were increased significantly in actively infected patients. Overall, we observed differential induction of IL-17-, IL-22- and IFN-γ-expressing CD4(+) T cells, IL-22-expressing granulocytes and proinflammatory cytokines in circulation and following antigenic stimulation in latent and active tuberculosis.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236009      PMCID: PMC3278699          DOI: 10.1111/j.1365-2249.2011.04520.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  65 in total

1.  IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia.

Authors:  Shean J Aujla; Yvonne R Chan; Mingquan Zheng; Mingjian Fei; David J Askew; Derek A Pociask; Todd A Reinhart; Florencia McAllister; Jennifer Edeal; Kristi Gaus; Shahid Husain; James L Kreindler; Patricia J Dubin; Joseph M Pilewski; Mike M Myerburg; Carol A Mason; Yoichiro Iwakura; Jay K Kolls
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

Review 2.  Induction and effector functions of T(H)17 cells.

Authors:  Estelle Bettelli; Thomas Korn; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2008-06-19       Impact factor: 49.962

Review 3.  IL-23 and IL-17 in tuberculosis.

Authors:  Shabaana A Khader; Andrea M Cooper
Journal:  Cytokine       Date:  2008-01-22       Impact factor: 3.861

4.  The phenolic glycolipid of Mycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence.

Authors:  Daniel Sinsimer; Gaelle Huet; Claudia Manca; Liana Tsenova; Mi-Sun Koo; Natalia Kurepina; Bavesh Kana; Barun Mathema; Salvatore A E Marras; Barry N Kreiswirth; Christophe Guilhot; Gilla Kaplan
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

5.  IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.

Authors:  Ken Sugimoto; Atsuhiro Ogawa; Emiko Mizoguchi; Yasuyo Shimomura; Akira Andoh; Atul K Bhan; Richard S Blumberg; Ramnik J Xavier; Atsushi Mizoguchi
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

6.  IL-21 and TGF-beta are required for differentiation of human T(H)17 cells.

Authors:  Li Yang; David E Anderson; Clare Baecher-Allan; William D Hastings; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo; David A Hafler
Journal:  Nature       Date:  2008-05-11       Impact factor: 49.962

7.  Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens.

Authors:  Yan Zheng; Patricia A Valdez; Dimitry M Danilenko; Yan Hu; Susan M Sa; Qian Gong; Alexander R Abbas; Zora Modrusan; Nico Ghilardi; Frederic J de Sauvage; Wenjun Ouyang
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

8.  IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis.

Authors:  Katharina Kreymborg; Ruth Etzensperger; Laure Dumoutier; Stefan Haak; Angelita Rebollo; Thorsten Buch; Frank L Heppner; Jean-Christophe Renauld; Burkhard Becher
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

9.  Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD.

Authors:  Camille Doe; Mona Bafadhel; Salman Siddiqui; Dhananjay Desai; Vijay Mistry; Paul Rugman; Margaret McCormick; Joanne Woods; Richard May; Matthew A Sleeman; Ian K Anderson; Christopher E Brightling
Journal:  Chest       Date:  2010-06-10       Impact factor: 9.410

10.  Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time.

Authors:  Liya Wassie; Abebech Demissie; Abraham Aseffa; Markos Abebe; Lawrence Yamuah; Hiwot Tilahun; Beyene Petros; Graham Rook; Alimuddin Zumla; Peter Andersen; T Mark Doherty
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

View more
  27 in total

Review 1.  The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection.

Authors:  Hongbo Shen; Zheng W Chen
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

Review 2.  Peripheral artery disease: epidemiology and global perspectives.

Authors:  F Gerry R Fowkes; Victor Aboyans; Freya J I Fowkes; Mary M McDermott; Uchechukwu K A Sampson; Michael H Criqui
Journal:  Nat Rev Cardiol       Date:  2016-11-17       Impact factor: 32.419

Review 3.  The current state of tuberculosis vaccines.

Authors:  David A Hokey; Ann Ginsberg
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

4.  The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction.

Authors:  Moises A Huaman; Eduardo Ticona; Gustavo Miranda; Richard J Kryscio; Raquel Mugruza; Ernesto Aranda; Paola L Rondan; David Henson; Cesar Ticona; Timothy R Sterling; Carl J Fichtenbaum; Beth A Garvy
Journal:  Clin Infect Dis       Date:  2018-03-05       Impact factor: 9.079

5.  Serum and CSF cytokines and matrix metalloproteinases in spinal tuberculosis.

Authors:  Tushar Patil; Ravindra Kumar Garg; Amita Jain; Madhu Mati Goel; Hardeep Singh Malhotra; Rajesh Verma; Gyan Prakash Singh; Praveen Kumar Sharma
Journal:  Inflamm Res       Date:  2014-12-12       Impact factor: 4.575

6.  Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer.

Authors:  David Cunningham; Qiuyang Zhang; Sen Liu; Keshab R Parajuli; Qiang Nie; Lin Ma; Allen Zhang; Zhenbang Chen; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

7.  Identification of immunological biomarkers which may differentiate latent tuberculosis from exposure to environmental nontuberculous mycobacteria in children.

Authors:  Yun-Gyoung Hur; Amelia C Crampin; Christina Chisambo; James Kanyika; Rein Houben; Richard Ndhlovu; Themba Mzembe; Maeve K Lalor; Jacky Saul; Keith Branson; Carolynne Stanley; Bagrey Ngwira; Neil French; Tom H Ottenhoff; Hazel M Dockrell; Patricia Gorak-Stolinska
Journal:  Clin Vaccine Immunol       Date:  2013-11-27

Review 8.  Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense.

Authors:  Jeremy P McAleer; Jay K Kolls
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

9.  Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection.

Authors:  Anuradha Bandaru; Kamakshi P Devalraju; Padmaja Paidipally; Rohan Dhiman; Sambasivan Venkatasubramanian; Peter F Barnes; Ramakrishna Vankayalapati; Vijayalakshmi Valluri
Journal:  Eur J Immunol       Date:  2014-04-23       Impact factor: 5.532

Review 10.  Th22 response induced by Mycobacterium tuberculosis strains is closely related to severity of pulmonary lesions and bacillary load in patients with multi-drug-resistant tuberculosis.

Authors:  B R Imperiale; A García; A Minotti; P González Montaner; L Moracho; N S Morcillo; D J Palmero; M Del Carmen Sasiain; S de la Barrera
Journal:  Clin Exp Immunol       Date:  2020-11-18       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.